Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Leukemia
- Sponsor
- Eastern Cooperative Oncology Group
- Enrollment
- 186
- Primary Endpoint
- Comprehensive view of microRNA expression by cytogenetic subgroup
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.
Detailed Description
OBJECTIVES: * To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo. * To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups. OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Comprehensive view of microRNA expression by cytogenetic subgroup
Time Frame: 1 year
MicroRNA expression in relation to clinical outcome
Time Frame: 1 year
Differential microRNA expression between normal B-cells and progenitors compared to B-ALL
Time Frame: 1 year